ADAPTIVE BIOTECHNOLOGIES CORPORATION Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$40.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$40.13M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$20.30M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$13.54M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $9.68M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$59.37M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$159.64M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$220.97M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$203.35M.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$40.13M 10-Q · filed 2026-08-04 | -$60.42M 10-Q · filed 2026-08-04 | -$73.96M derived: sum of 3 quarters · filed 2026-08-04 | -$64.28M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$20.30M 10-Q · filed 2026-05-05 | -$33.83M derived: sum of 2 quarters · filed 2026-05-05 | -$24.15M derived: sum of 3 quarters · filed 2026-05-05 | -$49.80M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$13.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.85M derived: sum of 2 quarters · filed 2026-02-26 | -$29.51M derived: sum of 3 quarters · filed 2026-08-04 | -$59.37M 10-K · filed 2026-02-26 |
| 2025-09-30 | $9.68M 10-Q · filed 2025-11-05 | -$15.97M derived: sum of 2 quarters · filed 2026-08-04 | -$45.83M 10-Q · filed 2025-11-05 | -$79.88M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$25.65M 10-Q · filed 2026-08-04 | -$55.52M 10-Q · filed 2026-08-04 | -$89.56M derived: sum of 3 quarters · filed 2026-08-04 | -$120.98M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$29.86M 10-Q · filed 2026-05-05 | -$63.91M derived: sum of 2 quarters · filed 2026-05-05 | -$95.33M derived: sum of 3 quarters · filed 2026-05-05 | -$141.65M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$34.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$65.47M derived: sum of 2 quarters · filed 2026-02-26 | -$111.79M derived: sum of 3 quarters · filed 2026-02-26 | -$159.64M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$31.42M 10-Q · filed 2025-11-05 | -$77.74M derived: sum of 2 quarters · filed 2025-11-05 | -$125.60M 10-Q · filed 2025-11-05 | -$194.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$46.32M 10-Q · filed 2025-08-05 | -$94.18M 10-Q · filed 2025-08-05 | -$163.18M derived: sum of 3 quarters · filed 2026-02-26 | -$212.86M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$47.85M 10-Q · filed 2025-05-01 | -$116.86M derived: sum of 2 quarters · filed 2026-02-26 | -$166.54M derived: sum of 3 quarters · filed 2026-02-26 | -$213.34M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$69.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$118.69M derived: sum of 2 quarters · filed 2026-02-26 | -$165.48M derived: sum of 3 quarters · filed 2026-02-26 | -$220.97M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$49.68M 10-Q · filed 2024-11-07 | -$96.48M derived: sum of 2 quarters · filed 2024-11-07 | -$151.97M 10-Q · filed 2024-11-07 | -$190.28M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$46.80M 10-Q · filed 2024-08-01 | -$102.29M 10-Q · filed 2024-08-01 | -$140.60M derived: sum of 3 quarters · filed 2025-03-03 | -$186.09M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$55.49M 10-Q · filed 2024-05-07 | -$93.80M derived: sum of 2 quarters · filed 2025-03-03 | -$139.29M derived: sum of 3 quarters · filed 2025-03-03 | -$192.39M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$38.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$83.80M derived: sum of 2 quarters · filed 2025-03-03 | -$136.91M derived: sum of 3 quarters · filed 2025-03-03 | -$203.35M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$45.49M 10-Q · filed 2023-11-09 | -$98.59M derived: sum of 2 quarters · filed 2023-11-09 | -$165.03M 10-Q · filed 2023-11-09 | -$227.53M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$53.10M 10-Q · filed 2023-08-02 | -$119.54M 10-Q · filed 2023-08-02 | -$182.04M derived: sum of 3 quarters · filed 2024-02-29 | -$238.25M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$66.44M 10-Q · filed 2023-05-03 | -$128.94M derived: sum of 2 quarters · filed 2024-02-29 | -$185.15M derived: sum of 3 quarters · filed 2024-02-29 | -$234.87M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$62.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$118.71M derived: sum of 2 quarters · filed 2024-02-29 | -$168.42M derived: sum of 3 quarters · filed 2024-02-29 | -$209.33M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$56.21M 10-Q · filed 2022-11-03 | -$105.92M derived: sum of 2 quarters · filed 2022-11-03 | -$146.83M 10-Q · filed 2022-11-03 | -$191.93M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$49.72M 10-Q · filed 2022-08-03 | -$90.62M 10-Q · filed 2022-08-03 | -$135.72M derived: sum of 3 quarters · filed 2023-02-14 | -$173.17M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | -$40.90M 10-Q · filed 2022-05-04 | -$86.01M derived: sum of 2 quarters · filed 2023-02-14 | -$123.45M derived: sum of 3 quarters · filed 2023-02-14 | |
| 2020-12-31 | -$45.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$82.55M derived: sum of 2 quarters · filed 2023-02-14 | -$146.00M 10-K · filed 2023-02-14 | |
| 2020-09-30 | -$37.45M 10-Q · filed 2021-11-03 | -$100.90M 10-Q · filed 2021-11-03 | ||
| 2019-12-31 | -$67.83M 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |